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Abstract
Background: Several coronavirus disease (COVID-19) vaccines have already been authorized and distributed in
different countries all over the world, including Bangladesh. Understanding public acceptance of such a novel
vaccine is vital, but little is known about the topic.
Objectives: This study aimed to investigate the determinants of intention to receive a COVID-19 vaccine and
willingness to pay (WTP) among people in Bangladesh.
Methods: An anonymous and online-based survey of Bangladeshi people (mean age = 29.96 ± 9.15 years; age
range = 18–60 years) was conducted using a self-reported questionnaire consisting of socio-demographics, COVID-
19 experience, and vaccination-related information as well as the health belief model (HBM). Multivariable logistic
regression was performed to determine the factors influencing COVID-19 vaccination intent and WTP.
Results: Of the 894 participants, 38.5% reported a definite intention to receive a COVID-19 vaccine, whereas 27%
had a probable intention, and among this intent group, 42.8% wanted to get vaccinated as soon as possible. Older
age, feeling optimistic about the effectiveness of COVID-19 vaccination, believing that vaccination decreases worries
and risk of COVID-19 infection, and being less concerned about side effects and safety of COVID-19 vaccination
under the HBM construct were found to be significant factors in COVID-19 vaccination intention. Most of the
participants (72.9%) were willing to pay for a COVID-19 vaccine, with a median (interquartile range [IQR]) amount of
BDT 400/US$ 4.72 (IQR; BDT 200–600/US$ 2.36–7.07) per dose. Factors associated with higher WTP were younger
age, being male, having higher education, residing in an urban area, having good self-rated health status, positivity
towards COVID-19 vaccination's effectiveness, and being worried about the likelihood of getting infected with
COVID-19. Participants who were COVID-19 vaccination intent preferred an imported vaccine over a domestically-
made vaccine (22.9% vs. 14.8%), while 28.2% preferred a routine immunization schedule.
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Conclusion: The findings indicate a considerable proportion of Bangladeshi people intended to get vaccinated and
had WTP for the COVID-19 vaccine. However, urgent education and awareness programs are warranted to alleviate
public skepticism regarding the COVID-19 vaccination.
Keywords: COVID-19 vaccine, Health belief model, Intention, Willingness to pay, Bangladesh
Introduction
The coronavirus disease 2019 (COVID-19), which
emerged in Wuhan, Hubei Province, China at the end of
2019, has caused a large global outbreak and has become
a major public health crisis [1, 2]. COVID-19 is a highly
transmittable viral infection caused by a novel strain of
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) [3]. On March 11, 2020, the World Health
Organization (WHO) declared the emergence of
COVID-19 as a pandemic [4] which has affected more
than 172 million people worldwide [5]. In Bangladesh,
approximately 802,305 confirmed cases of COVID-
19 were reported as of June 1, 2021, with a death toll of
12,660 [6]. This pandemic has severely affected people’s
physical and psychological well-being [7–11], health sys-
tem [12, 13] and also caused a major global economic
recession [14].
Vaccines are the most effective strategy to protect the
population from the devastating outcomes of COVID-19
[15, 16]. More than 287 potential vaccines are being devel-
oped and over 102 clinical trials have recently been re-
leased [16, 17]. Some have shown positive results, leading
to a number of countries approving specific vaccines for
implementation in vaccination programs. Meanwhile, by
June 1, 2021, over 1.9 billion doses of the COVID-19 vac-
cine had been administered in 231 locations [18].
Bangladesh began mass vaccination on February 8, 2021
[19]. Despite considerable progress towards the vaccin-
ation program, there is some hesitancy about the COVID-
19 vaccine [20]. Understanding public perception is cru-
cial in order to achieve high vaccination coverage, espe-
cially for newly emerging infectious diseases such as
COVID-19 [21–23]. According to recent studies on public
acceptance of COVID-19 vaccination, the intention to
take the vaccine ranged from 67 to 91% across countries
such as India, Saudi-Arabia, Canada, the United States,
and China [24–29]. There are multiple factors that may
influence people’s vaccination intentions. Several demo-
graphic factors and perception of the disease risk have
been found to be significantly associated with COVID-19
vaccination intent [28–30]. The health belief model
(HBM) is one of the most commonly used models to de-
termine factors associated with vaccination intention [31,
32] and has been used in many previous studies [33–35].
The HBM comprises several main constructs: perceived
susceptibility, severity, benefits, barriers, self-efficacy to
engage in a behavior, and cues to action [31]. Perceived
stigma is also used for identifying determinants of vaccin-
ation intent [25]. In terms of HBM, perceived benefits (i.e.
decreasing the chance of infection and making people less
worried about infection) and barriers (i.e., being con-
cerned about their efficacy) to vaccination were found to
be significant in affecting vaccination intention [35, 36]. In
addition, attitudes and experience regarding vaccination
history, and convenience have been shown to be the major
predictors of vaccination intention [29, 30].
Willingness-to-pay (WTP) refers to the maximum
amount, in monetary terms, that an individual would
be willing to allocate to obtain the benefits of a pro-
gram [37]. The decision to vaccinate depends on the
WTP of an individual in order to obtain increased
health benefits [38]. HBM constructs have been used
to explain WTP for influenza vaccination [34, 39]. In
a previous study, the WTP for COVID-19 vaccination
was found to be influenced by a variety of socioeco-
nomic factors [36]. In addition, no-affordability bar-
riers [35], as well as being aware of the perceived
risks associated with higher WTP [38]. More evidence
around public acceptance and WTP for the COVID-
19 vaccine is essential to evaluate the success of vac-
cination programs, and to provide insights into future
pricing considerations and demand forecasts.
To date, no research has been carried out in Bangladesh
on people’s acceptance of the COVID-19 vaccine, the
WTP, and the influencing factors and obstacles to vaccin-
ation coverage. The current study is aimed at determining
the intention and WTP for a COVID-19 vaccine and other
associated factors among people in Bangladesh.
Materials and methods
Study design, participants, and sampling
A cross-sectional online-based survey was carried out
between 10 December 2020 and 10 January 2021. The in-
clusion criteria for participating were age ≥ 18 years, so-
cial media users (Facebook, WhatsApp, etc.), and
currently living in Bangladesh. Incomplete surveys, indi-
viduals below 18 years old, and those who did not con-
sent to the survey were excluded. Participants were not
awarded any incentives or remuneration for taking part,
and all responses were anonymous.
Study procedure
The study used an online survey tool (Google Forms) to
collect data, which was advertised and disseminated
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across different social media platforms (Facebook, What-
sApp, etc.). Participants were asked, “Are you willing to
participate in this study voluntarily?” with “yes/no” re-
sponses. If the response was positive, they were given ac-
cess to the full questionnaire. Otherwise, a blank survey
form was submitted automatically. The questionnaire
was translated into Bangla (the native language of partic-
ipants) and then translated back to English and pre-
tested with 40 individuals before starting the final data
collection for acceptability and clarity. A total of 1032
participants completed the online survey form where
894 participants were included in the final analysis, fol-
lowing quality control and manual check procedures to
exclude incomplete and invalid surveys.
Sampling method





; n ¼ 1:96
2  0:5 1−0:5ð Þ
0:052
¼ 384:16 ≈ 384
Here,
n = number of samples
z = 1.96 (95% confidence level)
p = prevalence estimate (0.5)
q = (1-p)
d = precision limit or proportion of sampling error
(0.05)
Assuming a 10% non-response rate, a total of 423.5 ≈
424 sample size was estimated. However, the final sam-
ple exceeded this estimate.
Survey instruments
A self-reported semi-structured questionnaire was devel-
oped after reviewing previous studies on COVID-19 vac-
cine uptake [25, 29, 36]. The survey consisted of
questions about (1) socio-demographic information,
health status, COVID-19 experience, and vaccination-
related information; (2) beliefs about COVID-19 infec-
tion and COVID-19 vaccination; (3) intention to receive
the COVID-19 vaccine; (4) WTP for the COVID-19 vac-
cine; and (5) participant’s vaccine preference.
Socio-demographic, health status, COVID-19 experience,
and vaccination-related information
Participants’ details, including age, sex, marital status,
education level, monthly family income, number of chil-
dren in the family, and area of residence were recorded.
Participants were also asked to rate their overall health
status, and whether or not they had any existing chronic
diseases. Participants responded to their experience re-
garding COVID-19, whether or not they perceived
COVID-19 vaccination as an effective way to prevent
and control COVID-19 and whether or not they per-
ceived a doctor’s recommendation as an important fac-
tor for COVID-19 vaccination decision. Information
about the history of any vaccine hesitancy was also
obtained.
Beliefs about COVID-19 infection and COVID-19 vaccination
Participants’ beliefs about COVID-19 infection and
COVID-19 vaccination were measured using HBM [40].
The questions probed perceived stigma of COVID-
19 (four items), perceived susceptibility to COVID-19
(three items), perceived severity of COVID-19 (three
items), perceived benefits of COVID-19 vaccination (two
items), perceived barriers to getting a vaccination against
COVID-19 (five items), and cues to action (two items).
All construct questions of the health belief model were
measured on a 5-point Likert scale ranging from 1
(strongly disagree) to 5 (strongly agree) [35, 41]. For sim-
plification, the responses were recoded as “agree”
(strongly agree/agree) and “disagree” (strongly disagree/
disagree/not sure) during the final analysis.
Intention to receive a COVID-19 vaccine and willingness
to pay
Participant’s intention to receive a COVID-19 vaccine
was measured by asking “If a vaccine against COVID-19
infection was available, would you be willing to take it?”
Response options included “definitely not,” “probably
not,” “not sure,” “probably yes,” and “definitely yes.” For
our primary outcome, we dichotomized these responses
into “yes” (definitely/probably yes) or “no” (all other re-
sponses). To assess the WTP for a COVID-19 vaccine,
the question was “Would you be willing to pay out-of-
pocket for a COVID-19 vaccine?” with “yes/no” re-
sponses. Participants who responded positively (yes)
were asked “What is the maximum amount you are will-
ing to pay for a dose of the COVID-19 vaccine?” The re-
sponse options for price per dose were based on a 10-
point scale and ranged from BDT 100 (≈ US$ 1.18) to
BDT 1000 (≈ US$ 11.79). One United States Dollar
(US$) is equivalent to 84.81 Bangladeshi Taka (BDT).
Participant’s vaccine preference
Participants were asked “How soon would you like to re-
ceive a COVID-19 vaccine when it becomes available?”
with two response options: “I will receive the vaccine as
soon as possible” or “I will delay”. This was then
followed by a question, “Which type of COVID-19
vaccine would you prefer?” with response options:
“domestically-made vaccine”, “imported vaccine” or
“both are acceptable”. Lastly, participants were asked
"What kind of immunization schedule do you prefer for
the COVID-19 vaccination?” with response options:
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Table 1 Distribution of all variables and their associations with the intention to receive a COVID-19 vaccine
Variables Overall
N=894
Intention to receive a COVID-19 vaccine
Nob Yesa OR (95% CI) p-value aOR (95% CI) p-value
n (%) n (%) n (%)
Socio-demographics
Age
18-25 years 328 (36.7) 107 (34.7) 221 (37.7) Reference Reference
26-35 years 339 (37.9) 151 (49) 188 (32.1) 0.603 (0.44-0.826) 0.002 0.735 (0.502-1.075) 0.112
36-45 years 171 (19.1) 38 (12.3) 133 (22.7) 1.695 (1.104-2.6) 0.016 1.682 (1.032-2.742) 0.037
> 45 years 56 (6.3) 12 (3.9) 44 (7.5) 1.775 (0.9-3.5) 0.097 2.123 (0.936-4.815) 0.072
Sex
Male 444 (49.7) 151 (49) 293 (50) 1.04 (0.789-1.37) 0.782 – –
Female 450 (50.3) 157 (51) 293 (50) Reference
Marital status
Unmarried 511 (57.2) 175 (56.8) 336 (57.3) 1.016 (0.764-1.351) 0.914 – –
Married 357 (39.9) 121 (39.3) 236 (40.3) 0.608 (0.275-1.342) 0.218 – –
Divorced 26 (2.9) 12 (3.9) 14 (2.4) Reference
Education level
Bachelor 500 (55.9) 170 (55.2) 330 (56.3) 1.255 (0.913-1.723) 0.162 1.165 (0.787-1.726) 0.445
Master's and above 152 (17) 43 (14) 109 (18.6) 1.638 (1.058-2.537) 0.027 1.539 (0.908-2.606) 0.109
Intermediate or below 242 (27.1) 95 (30.8) 147 (25.1) Reference Reference
Monthly family income
< 20000 BDT 191 (21.4) 60 (19.5) 131 (22.4) 1.269 (0.857-1.88) 0.234 – –
20000-30000 BDT 193 (21.6) 58 (18.8) 135 (23) 1.353 (0.912-2.007) 0.133 – –
30000-40000 BDT 238 (26.6) 90 (29.2) 148 (25.3) 0.956 (0.667-1.37) 0.807 – –
> 40000 BDT 272 (30.4) 100 (32.5) 172 (29.4) Reference
Number of children in the family
0 443 (49.6) 152 (49.4) 291 (49.7) 1.436 (1.033-1.996) 0.031 1.486 (0.989-2.234) 0.057
1 227 (25.4) 60 (19.5) 167 (28.5) 2.087 (1.404-3.103) <0.001 1.658 (1.046-2.627) 0.081
≥2 224 (25.1) 96 (31.2) 128 (21.8) Reference Reference
Place of residence
Urban 700 (78.3) 238 (77.3) 462 (78.8) 1.096 (0.786-1.528) 0.589 – –
Rural 194 (21.7) 70 (22.7) 124 (21.2) Reference
Health status, COVID-19 experience, and vaccination-related information
Self-rated health status
Good 633 (70.8) 219 (71.1) 414 (70.6) 0.978 (0.722-1.325) 0.887 – –
Poor 261 (29.2) 89 (28.9) 172 (29.4) Reference
History of chronic disease
Yes 248 (27.7) 92 (29.9) 156 (26.6) 0.852 (0.628-1.156) 0.303 – –
No 646 (72.3) 216 (70.1) 430 (73.4) Reference
Ever tested for COVID-19
Yes 219 (24.5) 66 (21.4) 153 (26.1) 1.296 (0.933-1.8) 0.123 – –
No 675 (75.5) 242 (78.6) 433 (73.9) Reference
Ever diagnosed with COVID-19
Yes 167 (18.7) 56 (18.2) 111 (18.9) 1.052 (0.737-1.501) 0.782 – –
No 727 (81.3) 252 (81.8) 475 (81.1) Reference
Family member/friend ever infected by COVID-19
Yes 235 (26.3) 94 (30.5) 141 (24.1) Reference Reference
No 659 (73.7) 214 (69.5) 445 (75.9) 1.386 (1.019-1.886) 0.037 1.21 (0.838-1.747) 0.309
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Table 1 Distribution of all variables and their associations with the intention to receive a COVID-19 vaccine (Continued)
Variables Overall
N=894
Intention to receive a COVID-19 vaccine
Nob Yesa OR (95% CI) p-value aOR (95% CI) p-value
n (%) n (%) n (%)
Impact of COVID-19 on daily life
Severec 353 (39.5) 102 (33.1) 251 (42.8) 1.513 (1.134-2.019) 0.005 0.914 (0.593-1.408) 0.684
Littled 541 (60.5) 206 (66.9) 335 (57.2) Reference Reference
Impact of COVID-19 on studies/work
Severec 470 (52.6) 136 (44.2) 334 (57) 1.676 (1.269-2.214) <0.001 1.167 (0.762-1.787) 0.479
Littled 424 (47.4) 172 (55.8) 252 (43) Reference Reference
Impact of COVID-19 on physical/mental health
Severec 398 (44.5) 110 (35.7) 288 (49.1) 1.74 (1.31-2.311) <0.001 0.968 (0.639-1.466) 0.879
Littled 496 (55.5) 198 (64.3) 298 (50.9) Reference Reference
COVID-19 vaccination is an effective way to prevent and control COVID-19
Yes 704 (78.7) 188 (61) 516 (88.1) 4.705 (3.353-6.602) <0.001 2.709 (1.827-4.015) <0.001
No 190 (21.3) 120 (39) 70 (11.9) Reference Reference
Doctor’s recommendation is an important factor in vaccination decision-making
Yes 797 (89.1) 253 (82.1) 544 (92.8) 2.816 (1.835-4.322) <0.001 1.579 (0.935-2.664) 0.087
No 97 (10.9) 55 (17.9) 42 (7.2) Reference Reference
Previous refusals to get any type of vaccination
No 728 (81.4) 241 (78.2) 487 (83.1) 1.368 (0.967-1.934) 0.076 – –
Yes 166 (18.6) 67 (21.8) 99 (16.9) Reference
Perceived stigma of COVID-19
If I had COVID-19, I would be embarrassed
Agreee 232 (26) 63 (20.5) 169 (28.8) 1.576 (1.134-2.191) 0.007 1.117 (0.688-1.815) 0.654
Disagreef 662 (74) 245 (79.5) 417 (71.2) Reference Reference
If I had COVID-19, people would think badly of me
Agreee 230 (25.7) 63 (20.5) 167 (28.5) 1.55 (1.114-2.156) 0.009 0.695 (0.389-1.243) 0.220
Disagreef 664 (74.3) 245 (79.5) 419 (71.5) Reference Reference
If I had COVID-19, people would treat me differently.
Agreee 276 (30.9) 72 (23.4) 204 (34.8) 1.75 (1.279-2.396) <0.001 1.561 (0.917-2.657) 0.101
Disagreef 618 (69.1) 236 (76.6) 382 (65.2) Reference Reference
If I had COVID-19, I would not tell anyone
Agreee 142 (15.9) 49 (15.9) 93 (15.9) 0.997 (0.684-1.454) 0.988 – –
Disagreef 752 (84.1) 259 (84.1) 493 (84.1) Reference
Perceived susceptibility of contracting COVID-19
My chance of getting COVID-19 in the next few months is high
Agreee 226 (25.3) 71 (23.1) 155 (26.5) 1.2 (0.87-1.657) 0.267 – –
Disagreef 668 (74.7) 237 (76.9) 431 (73.5) Reference
I am worried about the likelihood of getting COVID 19
Agreee 406 (45.4) 112 (36.4) 294 (50.2) 1.762 (1.328-2.338) <0.001 1.643 (1.065-2.537) 0.025
Disagreef 488 (54.6) 196 (63.6) 292 (49.8) Reference Reference
Getting COVID-19 is currently a possibility for me
Agreee 297 (33.2) 93 (30.2) 204 (34.8) 1.235 (0.918-1.661) 0.164 – –
Disagreef 597 (66.8) 215 (69.8) 382 (65.2) Reference
Perceived severity of COVID-19
Complications from COVID-19 are serious
Agreee 412 (46.1) 120 (39) 292 (49.8) 1.556 (1.175-2.06) 0.002 0.997 (0.649-1.531) 0.987
Disagreef 482 (53.9) 188 (61) 294 (50.2) Reference Reference
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Table 1 Distribution of all variables and their associations with the intention to receive a COVID-19 vaccine (Continued)
Variables Overall
N=894
Intention to receive a COVID-19 vaccine
Nob Yesa OR (95% CI) p-value aOR (95% CI) p-value
n (%) n (%) n (%)
I will be very sick if I get infected with COVID-19
Agreee 365 (40.8) 104 (33.8) 261 (44.5) 1.575 (1.182-2.099) 0.002 0.946 (0.606-1.478) 0.808
Disagreef 529 (59.2) 204 (66.2) 325 (55.5) Reference Reference
I will be very afraid if I become infected with COVID-19
Agreee 401 (44.9) 122 (39.6) 279 (47.6) 1.386 (1.047-1.833) 0.022 0.871 (0.555-1.366) 0.547
Disagreef 493 (55.1) 186 (60.4) 307 (52.4) Reference Reference
Perceived benefits of COVID-19 vaccination
Vaccination is a good idea because I feel less worried about catching COVID-19
Agreee 329 (36.8) 46 (14.9) 283 (48.3) 5.32 (3.738-7.57) <0.001 2.351 (1.385-3.988) 0.002
Disagreef 565 (63.2) 262 (85.1) 303 (51.7) Reference Reference
Vaccination decreases my chance of getting COVID-19 or its complications
Agreee 378 (42.3) 59 (19.2) 319 (54.4) 5.042 (3.636-6.993) <0.001 3.083 (1.829-5.198) <0.001
Disagreef 516 (57.7) 249 (80.8) 267 (45.6) Reference Reference
Perceived barriers of COVID-19 vaccination
I am worried about the possible side effects of COVID-19 vaccination would interfere with my usual activities
Agreee 479 (53.6) 167 (54.2) 312 (53.2) 0.842 (0.689-1.072) 0.060 0.284 (0.216-0.561) 0.002
Disagreef 415 (46.4) 141 (45.8) 274 (46.8) Reference Reference
I am concerned about the efficacy of the COVID-19 vaccination
Agreee 470 (52.6) 164 (53.2) 306 (52.2) 0.96 (0.728-1.265) 0.770 – –
Disagreef 424 (47.4) 144 (46.8) 280 (47.8) Reference
I am concerned about the safety of the COVID-19 vaccination
Agreee 483 (54) 183 (59.4) 300 (51.2) 0.716 (0.542-0.947) 0.019 0.284 (0.187-0.429) <0.001
Disagreef 411 (46) 125 (40.6) 286 (48.8) Reference Reference
I am concerned about the affordability (high cost of the vaccine) of getting the COVID-19 vaccination
Agreee 450 (50.3) 151 (49) 299 (51) 1.083 (0.822-1.427) 0.570 – –
Disagreef 444 (49.7) 157 (51) 287 (49) Reference
I am concerned about faulty/fake COVID-19 vaccines
Agreee 539 (60.3) 188 (61) 351 (59.9) 0.953 (0.719-1.264) 0.740 – –
Disagreef 355 (39.7) 120 (39) 235 (40.1) Reference
Cues to action
I will only take the COVID-19 vaccine if I am given adequate information about it
Agreee 601 (67.2) 176 (57.1) 425 (72.5) 1.98 (1.482-2.645) <0.001 1.273 (0.787-2.058) 0.325
Disagreef 293 (32.8) 132 (42.9) 161 (27.5) Reference Reference
I will only take the COVID-19 vaccine if the vaccine is taken by many in the public
Agreee 505 (56.5) 144 (46.8) 361 (61.6) 1.827 (1.382-2.415) <0.001 0.878 (0.571-1.35) 0.553
Disagreef 389 (43.5) 164 (53.2) 225 (38.4) Reference Reference
OR Odds Ratio, CI Confidence Interval, aOR Adjusted Odds Ratios, BDT Bangladeshi Taka
aDefinitely yes/ probably yes
bDefinitely no/ probably no/ not sure
cVery severe/ severe
dVery little/ little/ fair
eStrongly agree/ agree
fStrongly disagree/ disagree/ not sure
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“routine immunization”, “emergency vaccination” or
“both are acceptable".
Statistical analysis
All statistical analyses were performed using IBM Statis-
tical Package for the Social Sciences software (SPSS; ver-
sion 25.0). Descriptive analyses, including frequencies,
percentages, means, standard deviations, etc. were com-
puted. Bivariate logistic regression analysis was per-
formed on the unadjusted estimates. Variables that were
significant (p < 0.05) in the bivariate logistic regression
analysis were included in the adjusted multivariable lo-




The sample comprised 894 survey responses. The partic-
ipants’ age ranged from 18 to 60 years with a mean age
of 29.96 (SD 9.15) years and approximately half of the
participants were female (50.3%). About 57.2% of the
participants were unmarried and 55.9% had a bachelor’s
degree, 30.4% reported having a monthly family income
of > 40,000 BDT and 78.3% resided in urban areas
(Table 1).
While the majority of participants reported good
health status (70.8%), 27.7% reported having chronic
underlying diseases. 18.7% of participants reported hav-
ing already been diagnosed with COVID-19. More than
a quarter of participants (26.3%) responded that their
family members had been infected with COVID-19. The
majority (89.1%) of participants perceived the doctor’s
recommendation as an important factor in their decision
to have the COVID-19 vaccine. While 18.6% reported
previous vaccine hesitancy (Table 1).
Health beliefs
The distribution of each item of the HBM is presented
in Table 1. Approximately 15.9–30.9% agreed with re-
gard to each construct-related stigma of COVID-19.
With regards to the perceived susceptibility of contract-
ing COVID-19, 74.7% of respondents disagreed that they
had the possibility of contracting COVID-19 in the next
few months; 45.4% were concerned about contracting
COVID-19, and 33.2% thought that contracting COVID-
19 was currently a possibility. Responses to questions
about the perceived severity of COVID-19 demonstrate
that less than half of respondents (46.1%) thought that
complications of COVID-19 were serious and they
would be very sick if they contracted COVID-19
(40.8%), or were afraid of contracting COVID-19
(44.9%). While the majority (78.7%) of participants per-
ceived that vaccination was an effective way to prevent
and control COVID-19, very few (36.8%) agreed that
vaccination would make them feel less worried about
contracting COVID-19, and vaccination would decrease
their chance of contracting COVID-19 or its complica-
tions (42.3%). With regards to perceived barriers to
COVID-19 vaccination, the majority of respondents
(50.3–60.3%) had concerns about COVID-19 vaccin-
ation, including the impact of side-effects on usual activ-
ities (53.6%), efficacy (52.6%), safety (54%), affordability
(50.3%), and validity (60.3%). In the cues to action sec-
tion of the survey, over two-thirds of respondents con-
firmed that they would only take a vaccine if they were
provided with adequate information (67.2%) and 43.5%
disagreed with taking the COVID-19 vaccine if the vac-
cine was not taken by many in the public.
COVID-19 vaccination intent
Overall, 65.5% of participants reported a posi-
tive intention to receive a COVID-19 vaccine (38.5% def-
initely yes, and 27.0% probably yes); whilst 34.5% were
unwilling or hesitant to be vaccinated against COVID-
19 (21.5% not sure, 8.6% probably not, and 4.4% defin-
itely not; Fig. 1). The results of bivariate and multivari-
able logistic regression of the intention to receive the
vaccine are presented in Table 1. Bivariate analysis
showed that the intention to receive the vaccine was sig-
nificantly (p < 0.05) associated with being older, having
higher education, having fewer children, having family
members not infected with COVID-19, the severe im-
pact of COVID-19 on participant's daily lives, studies/
work and physical/mental health, positivity towards
COVID-19 vaccination's effectiveness, and perceiving
the doctor's recommendation as an important factor in
vaccination decision making (Table 1). Multiple logistic
regression, using only those variables that were signifi-
cant in bivariate analysis, retained older age, positivity
towards the effectiveness of COVID-19 vaccination,
Fig. 1 COVID-19 vaccination intent (N = 894)
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worries about the likelihood of being infected, believ-
ing that vaccination will safeguard against catching
COVID-19 and decrease the risk of being infected with
COVID-19 or its complications, and being less aware of
the side-effects and safety of the COVID-19 vaccine
(Table 1).
Willingness to pay (WTP)
Almost three-quarters of participants (72.9%) were will-
ing to pay for the COVID-19 vaccine. The median
(interquartile range [IQR]) WTP of the willing group
was BDT400/US$ 4.72 (IQR; BDT 200–600/US$ 2.35–
7.07) per dose (Fig. 2). Bivariate analysis showed that
WTP was significantly (p < 0.05) associated with being
young, male, being single, having higher education,
urban residency, having good self-rated health status,
having no chronic underlying diseases, positivity towards
the effectiveness of COVID-19 vaccination, perceiving
the doctor's recommendation as an important factor in
vaccination decision making, being worried about the
likelihood of contracting COVID 19, believing that vac-
cination decreases the chance of contracting COVID-19
or if infected, its complications, and perception of being
vaccinated if given enough information about the
COVID-19 vaccine (Table 2). Figure 2 represents the
amount of money participants WTP for the COVID-19
vaccine. Multiple logistic regression, using only those
variables that were significant in bivariate analysis,
retained younger age, male, higher education, urban resi-
dent, having good self-rated health status, positivity to-
wards the effectiveness of COVID-19 vaccination, and
being worried about the likelihood of contracting
COVID-19 (Table 2).
Vaccine preference
Almost four in every ten participants who were COVID-
19 vaccine intet reported that they would receive the
vaccine as soon as possible (42.8%); whilst 57.2% re-
ported that they would delay. 14.8% reported a
domestically-made vaccine as their preference, 22.9%
preferred an imported vaccine and 62.3% had no prefer-
ence. In terms of immunization schedule, 28.2% pre-
ferred routine immunization, 21.5% an emergency
vaccination schedule and 50.3% had no preference
(Fig. 3).
Discussion
Vaccines are a key solution to halting the escalation of
pandemics such as COVID-19. The government of
Bangladesh began the COVID-19 vaccination roll-out on
February 8, 2021 [42]. As with any new vaccine, the
COVID-19 vaccine raises concerns. The present study
examined how likely people will be to take a COVID-
19 vaccine and investigate whether people are willing to
pay for it. Our finding represents one of the first esti-
mates of the intention to receive the vaccine among
Bangladeshi people and can be used to guide projections
of future vaccine uptake and successful implementation
of the COVID-19 vaccination program in Bangladesh.
In this study, the majority of participants (65.5%) re-
ported a definite or probable intention to receive a
COVID-19 vaccine, which is comparable with recent
studies conducted in Saudi Arabia and the United States
[25, 28]. A higher proportion of COVID-19 vaccine
intention has been reported in similar studies conducted
in China, India, Indonesia, and Malaysia, ranging from
83.5 to 94.3% [24, 27, 35, 36]. It may be possible that
when the study was conducted, the outbreak of COVID-
Fig. 2 Willingness to pay for the COVID-19 vaccine (N = 652)
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Table 2 Distribution of all studied variables and their associations with the willingness to pay for a COVID-19 vaccine





OR (95% CI) p-value aOR (95% CI) p-value
Socio-demographics
Age
18-25 years 111 (45.9) 217 (33.3) 1.173 (0.652-2.11) 0.594 1.148 (0.596-2.211) 0.680
26-35 years 73 (30.2) 266 (40.8) 2.186 (1.2-3.983) 0.011 2.068 (1.072-3.99) 0.030
36-45 years 37 (15.3) 134 (20.6) 2.173 (1.132-4.171) 0.02 1.715 (0.847-3.472) 0.134
> 45 years 21 (8.7) 35 (5.4) Reference Reference
Sex
Male 107 (44.2) 337 (51.7) 1.35 (1.003-1.816) 0.047 1.439 (1.044-1.985) 0.026
Female 135 (55.8) 315 (48.3) Reference Reference
Marital status
Unmarried 126 (52.1) 385 (59) 3.565 (1.607-7.909) 0.002 2.057 (0.847-4.993) 0.111
Married 102 (42.1) 255 (39.1) 2.917 (1.305-6.521) 0.159 2.299 (0.953-5.545) 0.064
Divorced 14 (5.8) 12 (1.8) Reference Reference
Education level
Bachelor 112 (46.3) 388 (59.5) 2.162 (1.549-3.018) <0.001 1.701 (1.169-2.476) 0.006
Master's and above 37 (15.3) 115 (17.6) 1.94 (1.234-3.049) 0.004 1.414 (0.859-2.327) 0.173
Intermediate or below 93 (38.4) 149 (22.9) Reference Reference
Monthly family income
< 20000 58 (24) 133 (20.4) 0.779 (0.516-1.177) 0.236 – –
20000-30000 53 (21.9) 140 (21.5) 0.898 (0.591-1.363) 0.613 – –
30000-40000 62 (25.6) 176 (27) 0.965 (0.648-1.437) 0.86 – –
> 40000 69 (28.5) 203 (31.1) Reference
Number of children in the family
0 124 (51.2) 319 (48.9) 1.029 (0.72-1.47) 0.875 – –
1 54 (22.3) 173 (26.5) 1.281 (0.841-1.953) 0.248 – –
≥2 64 (26.4) 160 (24.5) Reference
Place of residence
Urban 168 (69.4) 532 (81.6) 1.953 (1.393-2.737) <0.001 1.687 (1.16-2.454) 0.006
Rural 74 (30.6) 120 (18.4) Reference Reference
Health status, COVID-19 experience, and vaccination-related information
Self-rated health status
Good 146 (60.3) 487 (74.7) 1.941 (1.42-2.652) <0.001 1.713 (1.215-2.417) 0.002
Poor 96 (39.7) 165 (25.3) Reference Reference
History of chronic disease
No 162 (66.9) 484 (74.2) 1.423 (1.033-1.96) 0.031 1.187 (0.817-1.724) 0.369
Yes 80 (33.1) 168 (25.8) Reference Reference
Ever tested for COVID-19
Yes 61 (25.2) 158 (24.2) 0.949 (0.675-1.335) 0.764 – –
No 181 (74.8) 494 (75.8) Reference
Ever diagnosed with COVID-19
Yes 46 (19) 121 (18.6) 0.971 (0.666-1.415) 0.878 – –
No 196 (81) 531 (81.4) Reference
Family member/friend ever infected by COVID-19
Yes 70 (28.9) 165 (25.3) 0.833 (0.599-1.157) 0.275 – –
No 172 (71.1) 487 (74.7) Reference
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Table 2 Distribution of all studied variables and their associations with the willingness to pay for a COVID-19 vaccine (Continued)





OR (95% CI) p-value aOR (95% CI) p-value
Impact of COVID-19 on daily life
Severea 90 (37.2) 263 (40.3) 1.142 (0.842-1.548) 0.392 – –
Littleb 152 (62.8) 389 (59.7) Reference
Impact of COVID-19 on studies/work
Severea 122 (50.4) 348 (53.4) 1.126 (0.838-1.513) 0.431 – –
Littleb 120 (49.6) 304 (46.6) Reference
Impact of COVID-19 on physical/mental health
Severea 100 (41.3) 298 (45.7) 1.195 (0.887-1.611) 0.242 – –
Littleb 142 (58.7) 354 (54.3) Reference
COVID-19 vaccination is an effective way to prevent and control COVID-19
Yes 161 (66.5) 543 (83.3) 2.506 (1.789-3.511) <0.001 2.172 (1.486-3.176) <0.001
No 81 (33.5) 109 (16.7) Reference
Doctor’s recommendation is an important factor in vaccination decision-making
Yes 200 (82.6) 597 (91.6) 2.279 (1.479-3.512) <0.001 1.549 (0.938-2.557) 0.087
No 42 (17.4) 55 (8.4) Reference Reference
Previous refusals to get any type of vaccination
No 192 (79.3) 536 (82.2) 1.203 (0.831-1.743) 0.327 – –
Yes 50 (20.7) 116 (17.8) Reference
Perceived stigma of COVID-19
If I had COVID-19, I would be embarrassed
Agreec 64 (26.4) 168 (25.8) 0.965 (0.69-1.35) 0.837 – –
Disagreed 178 (73.6) 484 (74.2) Reference
If I had COVID-19, people would think badly of me
Agreec 66 (27.3) 164 (25.2) 0.896 (0.642-1.251) 0.520 – –
Disagreed 176 (72.7) 488 (74.8) Reference
If I had COVID-19, people would treat me differently.
Agreec 80 (33.1) 196 (30.1) 0.87 (0.635-1.194) 0.389 – –
Disagreed 162 (66.9) 456 (69.9) Reference
If I had COVID-19, I would not tell anyone
Agreec 46 (19) 96 (14.7) 0.736 (0.499-1.084) 0.120 – –
Disagreed 196 (81) 556 (85.3) Reference
Perceived susceptibility of contracting COVID-19
My chance of getting COVID-19 in the next few months is high
Agreec 61 (25.2) 165 (25.3) 1.005 (0.716-1.412) 0.976 – –
Disagreed 181 (74.8) 487 (74.7) Reference
I am worried about the likelihood of getting COVID 19
Agreec 93 (38.4) 313 (48) 1.479 (1.095-1.999) 0.011 1.403 (1.001-1.967) 0.049
Disagreed 149 (61.6) 339 (52) Reference Reference
Getting COVID-19 is currently a possibility for me
Agreec 80 (33.1) 217 (33.3) 1.01 (0.738-1.382) 0.950 – –
Disagreed 162 (66.9) 435 (66.7) Reference
Perceived severity of COVID-19
Complications from COVID-19 are serious
Agreec 123 (50.8) 289 (44.3) 0.77 (0.573-1.035) 0.084 – –
Disagreed 119 (49.2) 363 (55.7) Reference
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19 in Bangladesh was largely under control, and also
there was a lack of adequate information about the vac-
cine. Participants in this study had a low level of per-
ceived susceptibility to COVID-19, according to the
HBM construct, which is consistent with previous stud-
ies [35, 36] and suggests that the Bangladeshi people
were not aware of the possibility of the resurgence of
COVID-19, making them feel less vulnerable. Our find-
ings suggest that participants’ intention to receive a
COVID-19 vaccine was dependent on various socio-
demographic factors. In particular, older age was found
to be a significant influential factor for the COVID-19
Table 2 Distribution of all studied variables and their associations with the willingness to pay for a COVID-19 vaccine (Continued)





OR (95% CI) p-value aOR (95% CI) p-value
I will be very sick if I get infected with COVID-19
Agreec 104 (43) 261 (40) 0.886 (0.657-1.194) 0.426 – –
Disagreed 138 (57) 391 (60) Reference
I will be very afraid if I become infected with COVID-19
Agreec 107 (44.2) 294 (45.1) 1.036 (0.77-1.394) 0.815 – –
Disagreed 135 (55.8) 358 (54.9) Reference
Perceived benefits of COVID-19 vaccination
Vaccination is a good idea because I feel less worried about catching COVID-19
Agreec 78 (32.2) 251 (38.5) 1.316 (0.963-1.799) 0.085 – –
Disagreed 164 (67.8) 401 (61.5) Reference
Vaccination decreases my chance of getting COVID-19 or its complications
Agreec 85 (35.1) 293 (44.9) 1.507 (1.11-2.047) 0.009 1.15 (0.787-1.681) 0.47
Disagreed 157 (64.9) 359 (55.1) Reference Reference
Perceived barriers of COVID-19 vaccination
I am worried the possible side-effects of COVID-19 vaccination would interfere with my usual activities
Agreec 112 (46.3) 303 (46.5) 1.008 (0.75-1.355) 0.959 – –
Disagreed 130 (53.7) 349 (53.5) Reference
I am concerned about the efficacy of the COVID-19 vaccination
Agreec 124 (51.2) 346 (53.1) 1.076 (0.801-1.446) 0.627 – –
Disagreed 118 (48.8) 306 (46.9) Reference
I am concerned about the safety of the COVID-19 vaccination
Agreec 127 (52.5) 356 (54.6) 1.089 (0.81-1.464) 0.572 – –
Disagreed 115 (47.5) 296 (45.4) Reference
I am concerned about the affordability (high cost of the vaccine) of getting the COVID-19 vaccination
Agreec 131 (54.1) 319 (48.9) 0.812 (0.604-1.091) 0.167 – –
Disagreed 111 (45.9) 333 (51.1) Reference
I am concerned about faulty/fake COVID-19 vaccines
Agreec 147 (60.7) 392 (60.1) 0.974 (0.72-1.318) 0.866 – –
Disagreed 95 (39.3) 260 (39.9) Reference
Cues to action
I will only take the COVID-19 vaccine if I am given adequate information about it
Agreec 148 (61.2) 453 (69.5) 1.446 (1.063-1.966) 0.019 0.954 (0.643-1.415) 0.814
Disagreed 94 (38.8) 199 (30.5) Reference Reference
I will only take the COVID-19 vaccine if the vaccine is taken by many in the public
Agreec 125 (51.7) 380 (58.3) 1.308 (0.972-1.759) 0.076 – –
Disagreed 117 (48.3) 272 (41.7) Reference
OR Odds Ratio, CI Confidence Interval, aOR Adjusted Odds Ratios, BDT Bangladeshi Taka
aVery severe/ severe
bVery little/ little/ fair
cStrongly agree/ agree
dStrongly disagree/ disagree/ not sure
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vaccine intention. This finding is justified by the fact
that elderly people are at an increased risk of COVID-19
infection both in terms of its severity and also mortality
[43]. Our findings highlight the need for education inter-
vention focusing particularly on younger age groups.
The participants’ education level was also found to be a
significant factor in COVID-19 vaccine intention in the
bivariate analysis, although it was not significant in
the multivariate analysis. Similar results were shown in
other earlier studies in Bangladesh, illustrating that indi-
viduals with a higher educational background had more
knowledge and awareness regarding COVID-19 [44, 45].
The COVID-19 epidemic has had a significant impact
on people all across the world, affecting work, income,
and physical and mental health [46–48]. The present
study found that having family members who had been
infected and the perception of COVID-19’s impact on
daily life, studies/work, and physical/mental health were
significant factors in the bivariate analysis, agreeing with
a recent study among Chinese citizens [29]. Majority of
the study participants agreed that vaccination is an ef-
fective way to prevent and control COVID-19, and this
was a significant factor for participant’s intention to re-
ceive a vaccine, agreeing with 89.5% of Chinese residents
who thought that vaccination is an effective way to pre-
vent and control COVID-19 [29]. This positive attitude
towards COVID-19 vaccination and the significant im-
pact that it would have on their life explains the
intention to receive a vaccine among people in
Bangladesh. Multivariable analysis found that vaccin-
ation intention was associated with participant’s beliefs
[e.g., Health Belief Model (HBM)] towards COVID-19,
consistent with previous studies [34, 36, 49]. In
particular, our findings suggest that perceived suscepti-
bility to being infected with COVID-19 and the per-
ceived benefits of and barriers to COVID-19 vaccination
are the most important HBM constructs influencing par-
ticipants’ intention to receive a COVID-19 vaccine. Par-
ticipants with high perceived susceptibility to being
infected with COVID-19 expressed increased vaccination
intention, consistent with previous studies [25, 35].
While less than half of the participants (45.4%) were
worried about the likelihood of contracting COVID-19,
relatively few (25.3%) perceived themselves as at high
risk of becoming infected. This indicates the need to in-
crease public education and awareness about risk, in
order that preventive actions can be taken to improve
COVID-19 pandemic control [50].
The findings of this study also suggest partici-
pants' lower perceived benefits of COVID-19 vaccination
and relatively higher perceived barriers to getting
COVID-19 vaccination. In contrast, a similar study con-
ducted in China showed high perceived benefits and low
perceived barriers towards COVID-19 vaccination
among the participants [36]. This may be the reason
why Bangladeshi people showed a lower intention to re-
ceive a COVID-19 vaccine compared to Malaysian and
Chinese people [29, 35]. Public health intervention pro-
grams that focus on increasing awareness of the benefits
of COVID-19 vaccination and reducing the identified
barriers are therefore essential. The multivariate analysis
found concern about the safety of the COVID-19 vaccin-
ation as a significant barrier to vaccination intention,
with similar findings reported in other studies related to
the new vaccine [51], suggesting that information re-
garding the safety and efficacy standards should be made
Fig. 3 Vaccine preferences (N = 586)
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available to the general public. Another significant bar-
rier was the worry about possible side effects of the
COVID-19 vaccine. Bangladesh has experienced various
negative events associated with vaccine malpractices and
scandals, which have resulted in the public losing confi-
dence in the COVID-19 vaccines [52], which may be im-
plied in this study, as a considerable proportion of
reported concerns regarding the possibility of side-
effects of COVID-19 vaccines.
This study revealed that the majority of participants
(72.9%) were willing to pay for a COVID-19 vaccine.
This finding is comparable with a recent study in
Indonesia, which found 78.3% of participants had WTP
for a COVID-19 vaccine [38]. Multivariate analysis
found that WTP for a vaccine was significantly influ-
enced by socio-demographic factors such as younger
age, male sex, higher education level, and residing in an
urban area. Younger people reported higher WTP for a
COVID-19 vaccine, consistent with a recent study in
China [36]. A Malaysian study found higher education
levels, professional and managerial occupations, and
higher income groups were associated with higher WTP
[35]. An Indonesian study found that higher income and
high perceived risk among healthcare workers were asso-
ciated with higher WTP [38]. Good self-rated health sta-
tus and perceived effectiveness of the vaccine for
prevention and control of COVID-19 were also found as
significant factors for participants’ WTP for the COVID-
19 vaccine. In addition, the perceived severity of the
pandemic was also associated with a higher WTP. As
HBM constructs were significantly associated with WTP,
the HBM model should be used to inform the develop-
ment of interventions to promote vaccination against
COVID-19 as a priority for expenditure.
Over 40% of the participants who intended to re-
ceive a COVID-19 vaccine wanted to get vaccinated
as soon as possible. Studies conducted in China and
India found people’s intention to get prompt COVID-
19 vaccination was 52.5 and 65.8% respectively [24,
29]. The majority of vaccine intent participants re-
ported that both types of vaccine (domestically-made
or imported) were acceptable, while the imported
vaccine was more frequently preferred compared to
the domestically-made (22.9% vs 14.8%) in contrast to
a study in China which found that the majority of
participants preferred a domestically-made vaccine
over foreign-made (64.2% vs 11.9%) [36].
Our findings suggest that information about the safety
and efficacy of the COVID-19 vaccines should be made
public on a regular basis and timely health education and
communications by public health and government sources
such as healthcare professionals are critical to alleviating
public concerns as well as improving confidence and com-
pliance with the COVID-19 vaccine [23, 53].
There are some limitations to the current study that
need to be considered when interpreting the results.
Firstly, this study is a cross-sectional study design that
cannot establish causal inferences. Secondly, the responses
were based on self-reporting and may be subject to self-
reporting bias and a tendency to report socially desirable
responses. Thirdly, the use of an online survey and con-
venience sampling may result in sampling bias, so results
may not apply to the wider community due to a lack of
representative samples. Finally, the study was hypothetical
in nature as it was conducted before the COVID-19 vac-
cine became available in Bangladesh, so results may now
differ in practice. However, we believe that we have cap-
tured some really important information about the
COVID-19 vaccine. Further research is needed to gather
more data about the COVID-19 vaccine and WTP since
over 9.9 million doses of the COVID-19 vaccine have been
given in Bangladesh as of June 1, 2021 [18].
Conclusion
This study reflected that a sizeable proportion of Bangla-
deshi people intended to receive a COVID-19 vaccine.
Low perceived susceptibility to being infected with
COVID-19, as well as concern about side effects, and
the safety of any new vaccine were identified as key factors
in people's unwillingness or hesitation to receive a vaccine.
Furthermore, the majority of participants had a willingness
to pay for a COVID-19 vaccine. This study has important
implications for facilitating public health and government
authorities to design and deliver targeted intervention pro-
grams to enhance public acceptance of the COVID-19
vaccination in Bangladesh.
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